Research Integrity & Publication Ethics
Research Integrity at JMLPH
JMLPH upholds the integrity of the scientific record through standards-based editorial practice, transparent policies, and screening at every stage. The journal follows the recommendations of the ICMJE, the COPE code of conduct, and WAME.
Peer review
Every manuscript undergoes double-blind peer review by at least one national and one international expert. Author and reviewer identities are withheld from each other, and decisions rest solely on scientific merit, methodological quality, and ethical soundness — free from commercial influence or advertising.
Publication ethics we screen for
- Plagiarism: all submissions are screened before review.
- Competing interests: authors declare financial and non-financial interests; editors recuse themselves from manuscripts where a conflict exists.
- Ethics approval & consent: human-subjects research must report ethics-committee approval and participant consent; identifying patient details require written release.
- Authorship & AI use: authorship is limited to those who meet ICMJE criteria. Any generative-AI use must be disclosed in the methods, and AI cannot be listed as an author.
Trial registration & data availability
- Trial registration: prospective clinical trials should be registered in a WHO ICTRP–compliant registry or ClinicalTrials.gov before enrolment.
- Data availability statement: research articles should include a statement describing whether and how the underlying data can be accessed.
Key takeaway: JMLPH follows ICMJE, COPE, and WAME, with double-blind review, plagiarism screening, and clear ethics rules covering trial registration, data availability, and AI disclosure.
